In terms of antisense oligonucleotide (ASO) technology, which reduces the production of disease-causing proteins by binding to the target mRNA and either inhibiting its translation or facilitating its degradation, ASO technology has shown significant efficacy in SOD1 mutation-associated ALS (Lopez et al., 2022). Here, SOD1 is linked to amyotrophic lateral sclerosis.